AI Terminal
Spexis AG
Report Publication Announcement • Sep 4, 2019
957_rns_2019-09-04_08021b35-c493-4673-9125-e3aaae8e5f78.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 4 September 2019 17:38
Polyphor to present at the H.C. Wainwright Global Investment Conference
EQS Group-News: Polyphor AG / Key word(s): Conference
04.09.2019 / 17:38
Allschwil, Switzerland, September 4, 2019
Polyphor to present at the H.C. Wainwright Global Investment Conference
Polyphor AG (SIX: POLN) today announced that the company will present at the 21 st Annual H.C. Wainwright Global Investment Conference, taking place September 8-10, 2019 in New York City. Giacomo Di Nepi, CEO of Polyphor, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. A live webcast of the presentation will be accessible on Polyphor’s website on the Investor Relations page on the Calendar tab or under the following link: Polyphor Webcast . A replay of the webcast will be available for 90 days following the conclusion of the event.
Presentation details:
Date: September 9, 2019
Time: 03:25 – 03:50pm EDT
Location: The Lotte Palace Hotel, New York
Webcast: Polyphor Webcast
For further information please contact:
For Investors:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: [email protected]
For Media:
Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: [email protected]
About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer, and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com .
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=SOIKULNSGV
Document title: Polyphor_Wainwright_4.9.2019
End of Corporate News
| Language: | English |
| Company: | Polyphor AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | [email protected] |
| Internet: | www.polyphor.com |
| ISIN: | CH0106213793 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 868721 |
| End of News | EQS Group News Service |